Literature DB >> 15339841

Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall.

Sharlene M Day1, Jennifer L Reeve, Brian Pedersen, Diana M Farris, Daniel D Myers, Michael Im, Thomas W Wakefield, Nigel Mackman, William P Fay.   

Abstract

Leukocytes and leukocyte-derived microparticles contain low levels of tissue factor (TF) and incorporate into forming thrombi. Although this circulating pool of TF has been proposed to play a key role in thrombosis, its functional significance relative to that of vascular wall TF is poorly defined. We tested the hypothesis that leukocyte-derived TF contributes to thrombus formation in vivo. Compared to wild-type mice, mice with severe TF deficiency (ie, TF(-/-), hTF-Tg+, or "low-TF") demonstrated markedly impaired thrombus formation after carotid artery injury or inferior vena cava ligation. A bone marrow transplantation strategy was used to modulate levels of leukocyte-derived TF. Transplantation of low-TF marrow into wild-type mice did not suppress arterial or venous thrombus formation. Similarly, transplantation of wild-type marrow into low-TF mice did not accelerate thrombosis. In vitro analyses revealed that TF activity in the blood was very low and was markedly exceeded by that present in the vessel wall. Therefore, our results suggest that thrombus formation in the arterial and venous macrovasculature is driven primarily by TF derived from the blood vessel wall as opposed to leukocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339841     DOI: 10.1182/blood-2004-06-2225

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  93 in total

Review 1.  Tissue factor and thrombosis: The clot starts here.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

2.  Tissue-resident ecto-5' nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain.

Authors:  Danica Petrovic-Djergovic; Matthew C Hyman; Jessica J Ray; Diane Bouis; Scott H Visovatti; Takanori Hayasaki; David J Pinsky
Journal:  J Immunol       Date:  2012-01-30       Impact factor: 5.422

Review 3.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

4.  LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis.

Authors:  Wei Wang; Yang Tang; Ying Wang; Liana Tascau; Joanna Balcerek; Wei Tong; Ross L Levine; Carrie Welch; Alan R Tall; Nan Wang
Journal:  Circ Res       Date:  2016-07-18       Impact factor: 17.367

5.  Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi.

Authors:  Jaehyung Cho; Deane F Mosher
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

Review 6.  The harms and benefits of inflammatory and immune responses in vascular disease.

Authors:  Angel Chamorro; John Hallenbeck
Journal:  Stroke       Date:  2006-01-12       Impact factor: 7.914

Review 7.  Thrombus formation in vivo.

Authors:  Bruce Furie; Barbara C Furie
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

8.  Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively.

Authors:  Mikhail A Panteleev; Mikhail V Ovanesov; Dmitrii A Kireev; Aleksei M Shibeko; Elena I Sinauridze; Natalya M Ananyeva; Andrey A Butylin; Evgueni L Saenko; Fazoil I Ataullakhanov
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

Review 9.  Emerging paradigms in arterial thrombosis.

Authors:  James W Wisler; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

10.  Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.

Authors:  Frauke Swieringa; Marijke J E Kuijpers; Moniek M E Lamers; Paola E J van der Meijden; Johan W M Heemskerk
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.